S&P 500   4,516.20 (-1.33%)
DOW   34,450.47 (-0.55%)
QQQ   381.71 (-2.10%)
AAPL   161.04 (-1.66%)
MSFT   319.62 (-3.00%)
FB   305.60 (-1.54%)
GOOGL   2,823.77 (-1.24%)
AMZN   3,383.58 (-1.56%)
TSLA   1,027.34 (-5.28%)
NVDA   305.25 (-4.98%)
BABA   113.34 (-7.10%)
NIO   32.28 (-10.83%)
CGC   10.14 (-2.12%)
AMD   143.32 (-4.88%)
GE   93.07 (-2.27%)
MU   81.57 (-1.58%)
T   23.46 (+1.78%)
F   19.24 (-3.17%)
DIS   145.68 (-1.03%)
PFE   54.21 (+2.21%)
AMC   27.88 (-7.93%)
ACB   5.87 (-4.40%)
BA   198.46 (-1.94%)
S&P 500   4,516.20 (-1.33%)
DOW   34,450.47 (-0.55%)
QQQ   381.71 (-2.10%)
AAPL   161.04 (-1.66%)
MSFT   319.62 (-3.00%)
FB   305.60 (-1.54%)
GOOGL   2,823.77 (-1.24%)
AMZN   3,383.58 (-1.56%)
TSLA   1,027.34 (-5.28%)
NVDA   305.25 (-4.98%)
BABA   113.34 (-7.10%)
NIO   32.28 (-10.83%)
CGC   10.14 (-2.12%)
AMD   143.32 (-4.88%)
GE   93.07 (-2.27%)
MU   81.57 (-1.58%)
T   23.46 (+1.78%)
F   19.24 (-3.17%)
DIS   145.68 (-1.03%)
PFE   54.21 (+2.21%)
AMC   27.88 (-7.93%)
ACB   5.87 (-4.40%)
BA   198.46 (-1.94%)
S&P 500   4,516.20 (-1.33%)
DOW   34,450.47 (-0.55%)
QQQ   381.71 (-2.10%)
AAPL   161.04 (-1.66%)
MSFT   319.62 (-3.00%)
FB   305.60 (-1.54%)
GOOGL   2,823.77 (-1.24%)
AMZN   3,383.58 (-1.56%)
TSLA   1,027.34 (-5.28%)
NVDA   305.25 (-4.98%)
BABA   113.34 (-7.10%)
NIO   32.28 (-10.83%)
CGC   10.14 (-2.12%)
AMD   143.32 (-4.88%)
GE   93.07 (-2.27%)
MU   81.57 (-1.58%)
T   23.46 (+1.78%)
F   19.24 (-3.17%)
DIS   145.68 (-1.03%)
PFE   54.21 (+2.21%)
AMC   27.88 (-7.93%)
ACB   5.87 (-4.40%)
BA   198.46 (-1.94%)
S&P 500   4,516.20 (-1.33%)
DOW   34,450.47 (-0.55%)
QQQ   381.71 (-2.10%)
AAPL   161.04 (-1.66%)
MSFT   319.62 (-3.00%)
FB   305.60 (-1.54%)
GOOGL   2,823.77 (-1.24%)
AMZN   3,383.58 (-1.56%)
TSLA   1,027.34 (-5.28%)
NVDA   305.25 (-4.98%)
BABA   113.34 (-7.10%)
NIO   32.28 (-10.83%)
CGC   10.14 (-2.12%)
AMD   143.32 (-4.88%)
GE   93.07 (-2.27%)
MU   81.57 (-1.58%)
T   23.46 (+1.78%)
F   19.24 (-3.17%)
DIS   145.68 (-1.03%)
PFE   54.21 (+2.21%)
AMC   27.88 (-7.93%)
ACB   5.87 (-4.40%)
BA   198.46 (-1.94%)
NASDAQ:XCUR

Exicure Stock Forecast, Price & News

$0.46
-0.01 (-2.15%)
(As of 12/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.45
$0.47
50-Day Range
$0.46
$1.29
52-Week Range
$0.44
$2.83
Volume
154,412 shs
Average Volume
1.04 million shs
Market Capitalization
$40.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.74
30 days | 90 days | 365 days | Advanced Chart
Receive XCUR News and Ratings via Email

Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter.


Exicure logo

About Exicure

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.

Headlines

Exicure Update - Yahoo Finance
November 28, 2021 |  finance.yahoo.com
Exicure Update
November 26, 2021 |  finance.yahoo.com
Exicure Shareholder Notice
November 24, 2021 |  finance.yahoo.com
Chardan Capital Raises Exicure (NASDAQ:XCUR) Price Target to $7.00
November 23, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XCUR
Fax
N/A
Employees
63
Year Founded
N/A

Sales & Book Value

Annual Sales
$16.61 million
Book Value
$0.70 per share

Profitability

Net Income
$-24.67 million
Net Margins
-1,318.75%
Pretax Margin
-1,318.75%

Debt

Price-To-Earnings

Miscellaneous

Free Float
65,289,000
Market Cap
$40.12 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/19/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

2.22 out of 5 stars

Medical Sector

366th out of 1,391 stocks

Pharmaceutical Preparations Industry

161st out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -












Exicure (NASDAQ:XCUR) Frequently Asked Questions

Is Exicure a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exicure in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Exicure stock.
View analyst ratings for Exicure
or view top-rated stocks.

How has Exicure's stock been impacted by COVID-19?

Exicure's stock was trading at $1.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, XCUR stock has decreased by 72.6% and is now trading at $0.4553.
View which stocks have been most impacted by COVID-19
.

When is Exicure's next earnings date?

Exicure is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Exicure
.

How were Exicure's earnings last quarter?

Exicure, Inc. (NASDAQ:XCUR) released its quarterly earnings results on Friday, November, 19th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.18. The company earned ($3.68) million during the quarter, compared to the consensus estimate of $0.80 million. Exicure had a negative net margin of 1,318.75% and a negative trailing twelve-month return on equity of 87.09%.
View Exicure's earnings history
.

What price target have analysts set for XCUR?

3 brokerages have issued 1 year price targets for Exicure's shares. Their forecasts range from $2.25 to $6.00. On average, they expect Exicure's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 943.3% from the stock's current price.
View analysts' price targets for Exicure
or view top-rated stocks among Wall Street analysts.

Who are Exicure's key executives?

Exicure's management team includes the following people:
  • David A. Giljohann, Chief Executive Officer, Secretary & Director
  • Matthias G. Schroff, Chief Operating Officer
  • Brian C. Bock, Chief Financial Officer
  • Emil M. deGoma, Vice President-Clinical Development
  • Douglas E. Feltner, Chief Medical Officer

What is Exicure's stock symbol?

Exicure trades on the NASDAQ under the ticker symbol "XCUR."

Who are Exicure's major shareholders?

Exicure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Tybourne Capital Management HK Ltd. (8.31%), Prosight Management LP (5.82%), Geode Capital Management LLC (0.76%), Millennium Management LLC (0.68%), BlackRock Inc. (0.58%) and Dimensional Fund Advisors LP (0.17%). Company insiders that own Exicure stock include Aurasense Llc and Elias D Papadimas.
View institutional ownership trends for Exicure
.

Which institutional investors are selling Exicure stock?

XCUR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Geode Capital Management LLC, Dimensional Fund Advisors LP, Goldman Sachs Group Inc., and Tybourne Capital Management HK Ltd..
View insider buying and selling activity for Exicure
or view top insider-selling stocks.

Which institutional investors are buying Exicure stock?

XCUR stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, BlackRock Inc., HighTower Advisors LLC, UBS Group AG, and Raymond James & Associates.
View insider buying and selling activity for Exicure
or or view top insider-buying stocks.

How do I buy shares of Exicure?

Shares of XCUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exicure's stock price today?

One share of XCUR stock can currently be purchased for approximately $0.46.

How much money does Exicure make?

Exicure has a market capitalization of $40.12 million and generates $16.61 million in revenue each year. The company earns $-24.67 million in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Exicure have?

Exicure employs 63 workers across the globe.

What is Exicure's official website?

The official website for Exicure is www.exicuretx.com.

Where are Exicure's headquarters?

Exicure is headquartered at 2430 N. Halsted St., Chicago IL, 60614.

How can I contact Exicure?

Exicure's mailing address is 2430 N. Halsted St., Chicago IL, 60614. The company can be reached via phone at (847) 673-1700 or via email at [email protected].


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.